Jabra Enhance Select 200 vs Signia Pure C&G BCT IX
Side-by-side HearAdvisor lab results with SoundGrades, expert pick badges, and the same visualizations we use in product reviews.

Jabra Enhance Select 200
The Jabra Enhance Select 200 is a premium-priced OTC hearing aid that earned a B grade with a SoundScore of 3.9/5 in our lab testing, placing it in the top 35% of the OTC hearing aid category. At $1,695, this behind-the-ear device offers solid performance in several key areas, though it faces stiff competition from higher-scoring alternatives at similar price points. In our testing, this device showed particular strength in speech clarity during quiet listening situations, scoring 3.5/5—0.67 points above the category average. Own-voice comfort was another highlight at 3.4/5, finishing 0.89 points above average, which suggests users may find their own voice sounds more natural compared to many competitors. Music streaming scored 2.6/5, which is above the category average by 0.68 points but still only mixed in absolute terms. The device's limitations become apparent in challenging listening environments. Speech in noise scored just 1.4/5, slightly below the category average and low in absolute terms—a consideration for users who frequently encounter noisy restaurants or social gatherings. Feedback handling scored 4.0/5, which is strong in absolute terms though 0.54 points below the category average. The Enhance Select 200 has earned Expert's Choice Awards in both 2023 and 2024, reflecting its reliable real-world performance. With Bluetooth streaming for both iPhone and Android, rechargeable batteries, and hands-free capability, it offers modern convenience features. However, shoppers should note that several competitors in this price range—including the Lucid Tala and Audicus Omni 2—scored notably higher in our testing. This device is best suited for users who prioritize speech clarity in quieter environments and own-voice comfort over performance in noisy situations.
Choice

Signia Pure C&G BCT IX
The Signia Pure C&G BCT IX is a premium behind-the-ear prescription hearing aid released in 2025, earning an A grade with a SoundScore of 4.4/5 in our lab testing. Priced at $3,398, it ranks #16 among 39 prescription hearing aids tested. In our standardized testing, this device demonstrates particular strength in own-voice comfort, scoring 3.8/5—a solid result that sits 1.10 points above the category average. This makes it a noteworthy option for users who prioritize natural sound quality when speaking. Speech clarity also performs well, with speech-in-quiet at 3.8/5 (+0.39 points above average) and speech-in-noise at 2.5/5 (+0.43 points above average), though the latter remains mixed in absolute terms despite beating the category benchmark. Feedback handling presents an interesting picture: at 4.2/5, it's strong in absolute terms, though it falls 0.52 points below the category average of 4.72/5. Music streaming scores 2.7/5, essentially matching the category average. The device features rechargeable batteries, iPhone and Android streaming, and hands-free functionality. While the Pure C&G BCT IX delivers solid overall performance, shoppers in this premium price tier should note that competitors like the Phonak Sphere Infinio and Oticon Intent score higher in our testing. Budget-conscious buyers may also find comparable sound quality at lower price points from options like the Rexton Reach R-Li T80 at Costco. This hearing aid is best suited for users who value own-voice naturalness and reliable speech clarity in everyday listening situations.
We independently review each item we recommend and appreciate your trust and support. When you buy through our links, we may earn a commission. Learn More.
Performance metrics
Scale 1-5 (Tuned)
Lab metric by fit
Scale 1-5 (Tuned)
Speech level
Adjust input dB (Tuned)
Amplification (REIG)
Insertion gain at 65 dB (Tuned)
Fitting configuration for tuned fit